Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 3
2016 1
2020 8
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
SARS-CoV-2 and hepatitis.
Trevenzoli M, Guarnaccia A, Alberici I, Fassan M, Di Meco E, Farinati F, Cattelan AM. Trevenzoli M, et al. J Gastrointestin Liver Dis. 2020 Sep 9;29(3):473-475. doi: 10.15403/jgld-2747. J Gastrointestin Liver Dis. 2020. PMID: 32919428 Free article. No abstract available.
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
Tang H, Zhou L, Li X, Kinlaw AC, Yang JY, Moon AM, Barnes EL, Wang T. Tang H, et al. Int J Clin Pharm. 2021 Aug;43(4):1116-1122. doi: 10.1007/s11096-021-01311-5. Epub 2021 Jul 30. Int J Clin Pharm. 2021. PMID: 34328585 Free PMC article.
Objective to investigate the drug-induced liver injury associated with lopinavir-ritonavir among the patients with COVID-19. ...Results A total of 3,425 cases of drug-induced liver injury were reported in 19,782 patients wit …
Objective to investigate the drug-induced liver injury associated with lopinavir-ritonavir among the patients wi …
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19.
Yip TC, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, Tse YK, Hui DS, Chan HL, Wong GL. Yip TC, et al. Gut. 2021 Apr;70(4):733-742. doi: 10.1136/gutjnl-2020-321726. Epub 2020 Jul 8. Gut. 2021. PMID: 32641471
OBJECTIVE: Data on serial liver biochemistries of patients infected by different human coronaviruses (HCoVs) are lacking. The impact of liver injury on adverse clinical outcomes in coronavirus disease 2019 (COVID-19) patients remains unclear. ...
OBJECTIVE: Data on serial liver biochemistries of patients infected by different human coronaviruses (HCoVs) are lacking. The impact …
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
Khaykin P, Kotzerke P, Stephan C, Nisius G, Bickel M, Haberl A, Stürmer M, Kurowski M, Brodt R, von Hentig N. Khaykin P, et al. Ther Drug Monit. 2014 Apr;36(2):192-201. doi: 10.1097/FTD.0b013e3182a28c6a. Ther Drug Monit. 2014. PMID: 24632753 Clinical Trial.
Patient pairs were matched 1:2 for the parameters sex, age, weight, ethnicity, and drug formulation. RESULTS: None of the hepatitis-related cofactors (aspartate aminotransferase, alanine aminotransferase, gammaGT, HBe Ag, HBsAg, HCV-RNA PCR, HCV-therapy) had an influence o …
Patient pairs were matched 1:2 for the parameters sex, age, weight, ethnicity, and drug formulation. RESULTS: None of the hepatitis-r …
[Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
Tasias M, Aldeguer JL. Tasias M, et al. Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:18-21. doi: 10.1016/S0213-005X(14)70163-6. Enferm Infecc Microbiol Clin. 2014. PMID: 25542871 Review. Spanish.
The most important comorbid condition is chronic hepatitis, due to its frequency and because the biotransformation of LPV/r occurs in the liver. In these circumstances, it is important to evaluate the influence of liver failure on blood drug levels and how th …
The most important comorbid condition is chronic hepatitis, due to its frequency and because the biotransformation of LPV/r occurs in the …
Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.
Kao E, Shinohara M, Feng M, Lau MY, Ji C. Kao E, et al. Hepatology. 2012 Aug;56(2):594-604. doi: 10.1002/hep.25702. Epub 2012 Jun 11. Hepatology. 2012. PMID: 22407670 Free PMC article.
A portion of human immunodeficiency virus (HIV)-infected patients undergoing protease inhibitor (PI) therapy concomitantly consume or abuse alcohol leading to hepatic injury. The underling mechanisms are not known. We hypothesize that HIV PIs aggravate alcohol-induced …
A portion of human immunodeficiency virus (HIV)-infected patients undergoing protease inhibitor (PI) therapy concomitantly consume or abuse …
[Guidance on the special care of liver or kidney transplant recipients diagnosed with COVID-19].
Remport Á, Gerlei Z, Cseprekál O, Wagner L, Földes K, Marton A, Patonai A, Török S, Haboub-Sandil A, Varga M, Doros A, Smudla A, Fazakas J, Kóbori L. Remport Á, et al. Orv Hetil. 2020 Aug;161(32):1310-1321. doi: 10.1556/650.2020.31923. Orv Hetil. 2020. PMID: 32750019 Hungarian.
In the case of gastrointestinal or respiratory signs with fever, the discontinuation of mycophenolate or mTOR inhibitors is recommended with decrease of the trough levels of calcineurin inhibitors to the lowest effective limit. Stop (kidney transplanted patients) or decrease ( …
In the case of gastrointestinal or respiratory signs with fever, the discontinuation of mycophenolate or mTOR inhibitors is recommended with …
Early experience with remdesivir in SARS-CoV-2 pneumonia.
Durante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, Corcione A, Zampino R. Durante-Mangoni E, et al. Infection. 2020 Oct;48(5):779-782. doi: 10.1007/s15010-020-01448-x. Epub 2020 May 16. Infection. 2020. PMID: 32418190 Free PMC article.
One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. ...
One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients show …
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TT, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD. Lan NT, et al. PLoS One. 2014 Jan 22;9(1):e84866. doi: 10.1371/journal.pone.0084866. eCollection 2014. PLoS One. 2014. PMID: 24465443 Free PMC article. Clinical Trial.
BACKGROUND: Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of drug-drug interactions. Rifabutin has been proposed as an alternative rifamycin, but there is concern that the current recommend …
BACKGROUND: Rifampicin and protease inhibitors are difficult to use concomitantly in patients with HIV-associated tuberculosis because of …
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Gougis P, Fenioux C, Funck-Brentano C, Veyri M, Gligorov J, Solas C, Spano JP. Gougis P, et al. Eur J Cancer. 2020 Sep;136:1-3. doi: 10.1016/j.ejca.2020.05.027. Epub 2020 Jun 10. Eur J Cancer. 2020. PMID: 32610172 Free PMC article.
We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. Other drugs were studied for drug-drug interactions with antiviral medicines. A ready-to-use table synthesised these interactions between antiviral and anticancer drugs....
We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. Other drugs were studied for drug-drug …
14 results